Abstract
Novokinin (RPLKPW) was designed based on ovokinin (FRADHPFL), a vasorelaxing peptide derived from ovalbumin. Novokinin relaxed a mesenteric artery isolated from the spontaneously hypertensive rat (SHR) at 10-5 M, and reduced SHR blood pressure at a dose of 0.1 mg/kg (po.) emulsified in 30% egg yolk. Novokinin exhibited an affinity for the AT2 receptor (Ki = 7 x 10-6M), and its antihypertensive and vasorelaxing activities were blocked by PD123319, an AT2 receptor antagonist. The hypotensive effect of novokinin in normotensive mice was not observed in the AT2 receptor-knockout mice. Its antihypertensive and vasorelaxing activities in SHR were also blocked by CAY-10441, an antagonist of the IP receptor for prostaglandin I2 (PGI2) suggesting that these activities are mediated by the AT2 receptor, followed by the prostaglandin I2-IP receptor pathway.
Novokinin suppressed food intake after icv. or po. administration in mice. The anorexigenic activity was not observed in the AT2 receptor- knockout mice, but was observed in the AT1 receptor-knockout mice. The anorexigenic activities of novokinin and angiotensin II were blocked by PD123319, and ONO-AE3-208, an antagonist of the EP4 receptor suggesting that the anorexigenic activities of the AT2 agonists are mediated by the PGE2-EP4 receptor pathway downstream of the AT2 receptor.
Novokinin given icv. in mice antagonized the antinociceptive effect of morphine. The antiopiod activites of novokinin and angiotensin II were are blocked by PD123319, and by ONO-AE3-240, an antagonist of the EP3 receptor, suggesting that the antiopioid activities of AT2 agonists is mediated by the PGE2-EP3 receptor downstream of the AT2 receptor.
Keywords: Angiotensin, AT2 receptor, novokinin, compound 21, prostaglandin, vasorelaxation, opioid, food intake
Current Pharmaceutical Design
Title:The Pharmacological Effects of Novokinin; a Designed Peptide Agonist of the Angiotensin AT
Volume: 19 Issue: 17
Author(s): Masaaki Yoshikawa, Kousaku Ohinata and Yuko Yamada
Affiliation:
Keywords: Angiotensin, AT2 receptor, novokinin, compound 21, prostaglandin, vasorelaxation, opioid, food intake
Abstract: Novokinin (RPLKPW) was designed based on ovokinin (FRADHPFL), a vasorelaxing peptide derived from ovalbumin. Novokinin relaxed a mesenteric artery isolated from the spontaneously hypertensive rat (SHR) at 10-5 M, and reduced SHR blood pressure at a dose of 0.1 mg/kg (po.) emulsified in 30% egg yolk. Novokinin exhibited an affinity for the AT2 receptor (Ki = 7 x 10-6M), and its antihypertensive and vasorelaxing activities were blocked by PD123319, an AT2 receptor antagonist. The hypotensive effect of novokinin in normotensive mice was not observed in the AT2 receptor-knockout mice. Its antihypertensive and vasorelaxing activities in SHR were also blocked by CAY-10441, an antagonist of the IP receptor for prostaglandin I2 (PGI2) suggesting that these activities are mediated by the AT2 receptor, followed by the prostaglandin I2-IP receptor pathway.
Novokinin suppressed food intake after icv. or po. administration in mice. The anorexigenic activity was not observed in the AT2 receptor- knockout mice, but was observed in the AT1 receptor-knockout mice. The anorexigenic activities of novokinin and angiotensin II were blocked by PD123319, and ONO-AE3-208, an antagonist of the EP4 receptor suggesting that the anorexigenic activities of the AT2 agonists are mediated by the PGE2-EP4 receptor pathway downstream of the AT2 receptor.
Novokinin given icv. in mice antagonized the antinociceptive effect of morphine. The antiopiod activites of novokinin and angiotensin II were are blocked by PD123319, and by ONO-AE3-240, an antagonist of the EP3 receptor, suggesting that the antiopioid activities of AT2 agonists is mediated by the PGE2-EP3 receptor downstream of the AT2 receptor.
Export Options
About this article
Cite this article as:
Yoshikawa Masaaki, Ohinata Kousaku and Yamada Yuko,
The Pharmacological Effects of Novokinin; a Designed Peptide Agonist of the Angiotensin AT
DOI https://dx.doi.org/10.2174/1381612811319170006 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Microbial Efflux Pump Inhibition: Tactics and Strategies
Current Pharmaceutical Design Endothelial Remodelling and Intracellular Calcium Machinery
Current Molecular Medicine Intradialytic Hypertension: An Under-recognized Cardiovascular Risk Factor. What is the Evidence?
Current Hypertension Reviews Proniosomes in Transdermal Drug Delivery
Current Pharmaceutical Design TRPV4 Agonists and Antagonists
Current Topics in Medicinal Chemistry Treatment of Severe Cases of Pandemic (H1N1) 2009 Influenza: Review of Antivirals and Adjuvant Therapy
Recent Patents on Anti-Infective Drug Discovery Medication-Induced Nephrotoxicity in Older Patients
Current Drug Metabolism Propofol: Therapeutic Indications and Side-Effects
Current Pharmaceutical Design New Peptidic GnRH Antagonists Offer a Broad Range of Therapeutic Applications
Letters in Drug Design & Discovery Targeted Gene Deletion of Prolyl Hydroxylase Domain Protein 3 Triggers Angiogenesis and Preserves Cardiac Function by Stabilizing Hypoxia Inducible Factor 1 Alpha Following Myocardial Infarction
Current Pharmaceutical Design Hirsutism in Polycystic Ovary Syndrome: Pathophysiology and Management
Current Pharmaceutical Design Non-Celiac Gluten Sensitivity Triggers Gut Dysbiosis, Neuroinflammation, Gut-Brain Axis Dysfunction, and Vulnerability for Dementia
CNS & Neurological Disorders - Drug Targets The Therapeutic Potential and Usage Patterns of Cannabinoids in People with Spinal Cord Injuries: A Systematic Review
Current Neuropharmacology Heat Shock Protein Inhibitors for the Treatment of Fungal Infections
Recent Patents on Anti-Infective Drug Discovery Parkinson’s Disease: Recent Updates in the Identification of Human Dopa Decarboxylase Inhibitors
Current Drug Metabolism Gastrointestinal Dysmotility and Infections in Systemic Sclerosis- An Indian Scenario
Current Rheumatology Reviews Design, Development and Optimization of Ramipril Solid Lipid Nanoparticles Using Solvent Emulsification and Evaporation Method
Nanoscience & Nanotechnology-Asia Hepatic Encephalopathy: Cause and Possible Management with Botanicals
Recent Patents on Inflammation & Allergy Drug Discovery Current Immunotherapies for Renal Cell Carcinoma
Current Molecular Pharmacology A Review on Post-traumatic Stress Disorder (PTSD): Symptoms, Therapies and Recent Case Studies
Current Molecular Pharmacology